The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD

Philip M. Short, Peter A. Williamson, Douglas H. J. Elder, Samuel I. W. Lipworth, Stuart Schembri, Brian J. Lipworth

    Research output: Contribution to journalArticlepeer-review

    80 Citations (Scopus)


    Tiotropium has been shown to improve lung function, quality of life, and exacerbations and reduce mortality when compared with placebo in COPD. It remains unclear whether benefits are seen when tiotropium is used in conjunction with inhaled corticosteroids (ICSs) plus long-acting ß-agonists (LABAs).
    Original languageEnglish
    Pages (from-to)81-86
    Number of pages6
    Issue number1
    Publication statusPublished - Jan 2012


    • Obstructive pulmonary disease
    • Trial
    • Fluticasone
    • Salmeterol
    • Combination
    • Placebo
    • Asthma

    Cite this